Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05732402 · ClinicalTrials.gov registry record · Phase 1
An Open-label Study of Povetacicept in Autoantibody-Associated Glomerular Diseases
A Phase 1 study of Lupus Nephritis and Immunoglobulin A Nephropathy, sponsored by Alpine Immune Sciences.
- Active
- Registry status
- Phase 1
- Development phase
- 72
- Enrollment target
- 20
- Study locations
NCT05732402 is a Phase 1 study of Lupus Nephritis and Immunoglobulin A Nephropathy that is active but no longer recruiting, run by Alpine Immune Sciences. The registered enrollment target is 72 participants, below the 308-participant average among 30 other Lupus Nephritis trials with a reported enrollment target (77% lower). The trial reports 20 study locations across 14 states.
The verdict
NCT05732402, a Phase 1 study of Lupus Nephritis and Immunoglobulin A Nephropathy, is active but no longer recruiting, sponsored by Alpine Immune Sciences.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 72 participants
- Enrollment target
- 20
- Study locations
Study Summary
The goal of this clinical study is to evaluate multiple dose levels of povetacicept in adults with immunoglobulin A (IgA) nephropathy (IgAN), primary membranous nephropathy (pMN), lupus-related kidney disease (lupus nephritis - LN), or anti-neutrophil cytoplasmic antibody (ANCA) associated vasculitis (AAV) to determine if povetacicept is safe and potentially beneficial in treating these diseases. During the study treatment period, participants will receive povetacicept approximately every 4 weeks for 6 months, with the possibility of participating in a 6-month treatment extension period and an optional 52-week treatment extension period. Participants with IgAN and pMN may also receive povetacicept for an additional 52 weeks, if eligible.
Conditions Studied
Interventions
- DRUG Povetacicept
Study Locations (20)
Arizona
- Investigational Site (523) - Phoenix
- Investigational Site (501) - Phoenix
- Investigational Site (524) - Tucson
Texas
- Investigational Site (118) - Colleyville
- Investigational Site (516) - Houston
- Investigational Site (526) - Irving
Florida
- Investigational Site (512) - Orlando
- Investigational Site (525) - Tamarac
New York
- Investigational Site (511) - Albany
- Investigational Site (508) - Brooklyn
California
- Investigational Site (506) - Valencia
Colorado
- Investigational Site (513) - Arvada
Georgia
- Investigational Site (502) - Lawrenceville
Maryland
- The Johns Hopkins University School of Medicine - Baltimore
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 72 participants |
| Start Date | 2023-03-15 |
| Est. Completion | 2028-03-02 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05732402
The ClinicalTrials.gov registry entry for NCT05732402 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 72 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 308-participant average among 30 other Lupus Nephritis trials with a reported enrollment target (77% lower). The listed sponsor is Alpine Immune Sciences, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 4 conditions, with Lupus Nephritis appearing as the primary indexed condition, and to 1 intervention - of which Povetacicept is the first listed.
NCT05732402 reports 20 study locations spanning 14 distinct geographic areas - top geographies include Arizona, Texas, Florida.
Frequently Asked Questions
What is clinical trial NCT05732402 about?
NCT05732402 is a clinical study titled "An Open-label Study of Povetacicept in Autoantibody-Associated Glomerular Diseases". The goal of this clinical study is to evaluate multiple dose levels of povetacicept in adults with immunoglobulin A (IgA) nephropathy (IgAN), primary membranous nephropathy (pMN), lupus-related kidney disease (lupus nephritis - LN), or anti-neutrophil cytoplasmic antibody (ANCA) associated vasculiti...
What is the current status of trial NCT05732402?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 72 participants. The study started on 2023-03-15. Estimated completion is 2028-03-02.
What conditions does trial NCT05732402 study?
This clinical trial studies the following conditions: Lupus Nephritis, Immunoglobulin A Nephropathy, Membranous Nephropathy, Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis.
What interventions are being tested in trial NCT05732402?
The interventions under investigation include: Povetacicept (DRUG).
Who is sponsoring clinical trial NCT05732402?
This trial is sponsored by Alpine Immune Sciences, which has 5 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05732402 being conducted?
This trial has 20 study locations across Arizona, California, Colorado, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Lupus Nephritis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Safety and Efficacy Study Evaluating CTX112 in Adult Subjects With Refractory Autoimmune Disease
RECRUITING · Phase 1
-
Phase I/II Study of AD-PluReceptor Plus Tafasitamab-cxix and Lymphodepleting Chemotherapy in Patients With Autoimmune Disorders
RECRUITING · Phase 1
-
A Phase 1/2 Study of NKX019 in Subjects With Autoimmune Disease (Ntrust-1)
RECRUITING · Phase 1
-
RESET-SLE: A Phase 1/2 Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Systemic Lupus Erythematosus
RECRUITING · Phase 1
-
A Study to Learn More About the Safety and Effects of Felzartamab in Adults With Lupus Nephritis Aged 18 to 75 Years Old
ACTIVE NOT RECRUITING · Phase 1
-
KYSA-1: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell (CD19 CAR T) Therapy, in Subjects With Refractory Lupus Nephritis
ACTIVE NOT RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.